News

Public · Published

GSK to nearly double cancer drugs in late-stage trials next year: WSJ

GSK is investing more in cancer drugs. A leading scientist said the number of its cancer medicines in late-stage trials should nearly double next year. GSK currently has five approved cancer medicines, with a sixth expected in a few weeks.

Published:

Updated:

What happened

GSK is investing more in cancer drugs. A leading scientist said the number of its cancer medicines in late-stage trials should nearly double next year. GSK currently has five approved cancer medicines, with a sixth expected in a few weeks.

Confirmed

Global impact / market context

More late-stage trials mean GSK will spend more on research and development, which raises costs before any new drug earns revenue. If trials succeed, new approvals could add future sales and help GSK grow beyond its current five cancer medicines.

Analyst inference

GSK is returning to cancer after leaving the field nearly a decade ago. Rising cancer cases across several patient groups support demand for new treatments. Investors may weigh higher research spending against the potential for new products and future revenue.

Analyst inference

What to watch

  1. Watch whether GSK receives approval for its sixth cancer medicine in the coming weeks, as the scientist expects, since this would raise its count of approved cancer drugs. Confirmed
  2. Track whether GSK's late-stage cancer trial portfolio nearly doubles next year as planned, because delays or failures would reduce the number of potential new medicines. Proposed
  3. Watch GSK's research spending and trial results, since higher costs cut near-term profit while positive results could support future sales from new cancer drugs. Analyst inference

Evidence